Stay updated on Immunotherapy with Chemo in HER2-neg IBC Clinical Trial
Sign up to get notified when there's something new on the Immunotherapy with Chemo in HER2-neg IBC Clinical Trial page.

Latest updates to the Immunotherapy with Chemo in HER2-neg IBC Clinical Trial page
- Check5 days agoChange DetectedA service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference0.4%
- Check12 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Notably, the information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference0.5%
- Check26 days agoChange DetectedThe expected modernization of the ClinicalTrials.gov data ingest has been postponed from June 2025 to July 2025, and the revision version has been updated from v2.16.2 to v2.16.4.SummaryDifference0.5%
- Check33 days agoNo Change Detected
- Check40 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check48 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference0.6%
- Check55 days agoChange DetectedThe page has removed a citation regarding the NeoALTTO study on Lapatinib with trastuzumab for HER2-positive early breast cancer, which was previously included.SummaryDifference0.2%
Stay in the know with updates to Immunotherapy with Chemo in HER2-neg IBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunotherapy with Chemo in HER2-neg IBC Clinical Trial page.